EPIK Biosciences Expands Ketamine and DXM Drug Portfolio
AUSTIN, Texas — September 10, 2026 EPIK Biosciences announced continued progress in developing proprietary synergistic combination medicines targeting mental...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
AUSTIN, Texas — September 10, 2026 EPIK Biosciences announced continued progress in developing proprietary synergistic combination medicines targeting mental...
BERKELEY HEIGHTS, N.J., July 13, 2026 Tonix Pharmaceuticals announced a major managed Medicare payer agreement that will expand pharmacy...
BERKELEY HEIGHTS, N.J., May 28, 2026 Tonix Pharmaceuticals presented new real-world data at the 2026 American Society of Clinical...
